Entinostat, Nivolumab and Ipilimumab for Women with Advanced HER2-Negative Breast Cancer: A Phase Ib Trial

Investigators reported the results of 24 women, 50% with hormone receptor-positive breast cancer and 50% with advanced TNBC, treated with entinostat + nivolumab + ipilimumab from the dose escalation and expansion cohort of ETCTN-9844.